



Item 2.02 Results of Operations and Financial Conditions.

On May 15, 2017, Cleveland BioLabs, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2017. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit

No. Description

99.1 Press Release titled “Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress”, dated May 15, 2017

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cleveland BioLabs, Inc.

Date: May 15, 2017 By: /s/ YAKOV KOGAN

Name: Yakov Kogan

Title: Chief Executive Officer